Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lesogaberan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lesogaberan SCHEMBL349233 | 1.00 | — | — | |
| Lesogaberan SCHEMBL349234 | 1.00 | — | — | |
| SCHEMBL1888584 | 0.82 | — | — | |
| SCHEMBL1890963 | 0.74 | — | — | |
| SCHEMBL1884028 | 0.74 | — | — | |
| SCHEMBL1883348 | 0.74 | — | — | |
| SCHEMBL3439120 | 0.72 | — | — | |
| SCHEMBL349589 | 0.72 | — | — | |
| SCHEMBL3439121 | 0.72 | — | — | |
| SCHEMBL351642 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536194-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | EsoCap AG (CH) | 2025-04-16 | — | — | EP | claimed |
| WO-2023237426-A1 | DRUG DELIVERY SYSTEM COMPRISING A REFLUX INHIBITOR FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2023-12-14 | — | — | WO | claimed |
| US-20210205248-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-08 | — | — | US | claimed |
| EP-3753410-A2 | COMBINATIONS COMPRISING GABA AGONISTS IN TREATMENT OF HYPERGLYCEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-23 | — | — | EP | claimed |
| US-20130251671-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-26 | — | — | US | claimed |
| EP-2621282-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | The Regents of the University of California (US) | 2013-08-07 | — | — | EP | claimed |
| CN-103228142-A | GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes | UNIV CALIFORNIA | 2013-07-31 | — | — | CN | claimed |
| WO-2012050907-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-19 | — | — | WO | claimed |
| US-20110054216-A1 | NOVEL PROCESS FOR MAKING (2R)-(3-AMINO-2-FLUOROPROPYL)PHOSPHINIC ACID FORM A | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | claimed |
| US-20110034420-A1 | NOVEL CRYSTALLINE FORM B OF (2R)-(3-AMINO-2-FLUOROPROPYL)PHOSPHINIC ACID | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | claimed |
| US-6576626-B2 | Treating gastro-oesophageal reflux disease | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | claimed |
| JP-2003516407-A | — | — | 2003-05-13 | — | — | JP | claimed |
| JP-2003516346-A | — | — | 2003-05-13 | — | — | JP | claimed |
| CN-1413104-A | New (aminopropyl) methylphosphinic acids | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | CN | claimed |
| WO-2002100869-A1 | NEW NAPSYLATE SALTS I | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-20020156053-A1 | New aminopropylphosphinic acids | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2002-10-24 | — | — | US | claimed |
| EP-1239843-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | claimed |
| EP-1240172-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | claimed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | claimed |
| WO-2001041743-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | claimed |